FEMB_STAAR
ID FEMB_STAAR Reviewed; 419 AA.
AC Q6GH30;
DT 01-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT 19-JUL-2004, sequence version 1.
DT 25-MAY-2022, entry version 93.
DE RecName: Full=Aminoacyltransferase FemB;
DE EC=2.3.2.18;
DE AltName: Full=Factor essential for expression of methicillin resistance B;
DE AltName: Full=N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-(N6-triglycine)-D-alanyl-D-alanine-diphosphoundecaprenyl-N-acetylglucosamine:glycine glycyltransferase;
GN Name=femB; OrderedLocusNames=SAR1388;
OS Staphylococcus aureus (strain MRSA252).
OC Bacteria; Firmicutes; Bacilli; Bacillales; Staphylococcaceae;
OC Staphylococcus.
OX NCBI_TaxID=282458;
RN [1]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=MRSA252;
RX PubMed=15213324; DOI=10.1073/pnas.0402521101;
RA Holden M.T.G., Feil E.J., Lindsay J.A., Peacock S.J., Day N.P.J.,
RA Enright M.C., Foster T.J., Moore C.E., Hurst L., Atkin R., Barron A.,
RA Bason N., Bentley S.D., Chillingworth C., Chillingworth T., Churcher C.,
RA Clark L., Corton C., Cronin A., Doggett J., Dowd L., Feltwell T., Hance Z.,
RA Harris B., Hauser H., Holroyd S., Jagels K., James K.D., Lennard N.,
RA Line A., Mayes R., Moule S., Mungall K., Ormond D., Quail M.A.,
RA Rabbinowitsch E., Rutherford K.M., Sanders M., Sharp S., Simmonds M.,
RA Stevens K., Whitehead S., Barrell B.G., Spratt B.G., Parkhill J.;
RT "Complete genomes of two clinical Staphylococcus aureus strains: evidence
RT for the rapid evolution of virulence and drug resistance.";
RL Proc. Natl. Acad. Sci. U.S.A. 101:9786-9791(2004).
CC -!- FUNCTION: Catalyzes the formation of the pentaglycine interpeptide
CC bridge, which is characteristic of the S.aureus peptidoglycan. Adds
CC glycines 4 and 5 of the pentaglycine bridge, using glycyl-tRNA(Gly) as
CC donor. Involved in resistance to methicillin (By similarity).
CC {ECO:0000250}.
CC -!- CATALYTIC ACTIVITY:
CC Reaction=2 glycyl-tRNA(Gly) + MurNAc-L-Ala-D-isoglutaminyl-L-Lys-(N(6)-
CC tri-Gly)-D-Ala-D-Ala-diphospho-di-trans,octa-cis-undecaprenyl-GlcNAc
CC = 2 H(+) + MurNAc-L-Ala-D-isoglutaminyl-L-Lys-(N(6)-penta-Gly)-D-Ala-
CC D-Ala-diphospho-di-trans,octa-cis-undecaprenyl-GlcNAc + 2 tRNA(Gly);
CC Xref=Rhea:RHEA:30443, Rhea:RHEA-COMP:9664, Rhea:RHEA-COMP:9683,
CC ChEBI:CHEBI:15378, ChEBI:CHEBI:62235, ChEBI:CHEBI:62236,
CC ChEBI:CHEBI:78442, ChEBI:CHEBI:78522; EC=2.3.2.18;
CC -!- SUBUNIT: Homodimer. Interacts with FemA (By similarity). {ECO:0000250}.
CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC -!- SIMILARITY: Belongs to the FemABX family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; BX571856; CAG40386.1; -; Genomic_DNA.
DR RefSeq; WP_000673098.1; NC_002952.2.
DR AlphaFoldDB; Q6GH30; -.
DR SMR; Q6GH30; -.
DR KEGG; sar:SAR1388; -.
DR HOGENOM; CLU_048411_1_0_9; -.
DR OMA; GPYAMHW; -.
DR OrthoDB; 891566at2; -.
DR Proteomes; UP000000596; Chromosome.
DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR GO; GO:0016755; F:aminoacyltransferase activity; IEA:InterPro.
DR GO; GO:0071555; P:cell wall organization; IEA:UniProtKB-KW.
DR GO; GO:0009252; P:peptidoglycan biosynthetic process; IEA:UniProtKB-KW.
DR GO; GO:0008360; P:regulation of cell shape; IEA:UniProtKB-KW.
DR GO; GO:0046677; P:response to antibiotic; IEA:UniProtKB-KW.
DR InterPro; IPR016181; Acyl_CoA_acyltransferase.
DR InterPro; IPR003447; FEMABX.
DR Pfam; PF02388; FemAB; 1.
DR SUPFAM; SSF55729; SSF55729; 2.
DR PROSITE; PS51191; FEMABX; 1.
PE 3: Inferred from homology;
KW Acyltransferase; Antibiotic resistance; Cell shape;
KW Cell wall biogenesis/degradation; Cytoplasm; Peptidoglycan synthesis;
KW Transferase.
FT CHAIN 1..419
FT /note="Aminoacyltransferase FemB"
FT /id="PRO_0000204741"
SQ SEQUENCE 419 AA; 49676 MW; 9C5C90C340E86288 CRC64;
MKFTELTVTE FDNFVQNPSL ESHYFQVKEN IVTRENDGFE VVLLGIKDDN NKVIAASLFS
KIPTMGSYVY YSNRGPVMDF SDLGLVDYYL KELDKYLQQH QCLYVKLDPY WLYHLYDKDI
VPFEGREKND ALVNLFKSHG YEHHGFTTEY DTSSQVRWMG VLNLEGKTPE TLKKTFDSQR
KRNINKAINY GVKVRFLERD EFNLFLDLYR ETEERAGFVS KTDDYFYNFI DTYGDKVLVP
LAYIDLDEYV LKLQQELNDK ENRRDQMMAK ENKSDKQMKK IAELDKQIDH DQHELLNASE
LSKTDGPILN LASGVYFANA YEVNYFSGGS SEKYNQFMGP YMMHWFMINY CFDNGYDRYN
FYGLSGDFTE NSEDYGVYRF KRGFNVQIEE LIGDFYKPIH KVKYWLFTTL DKLRKKLKK